ARMISTICE CAPITAL, LLC - Q1 2016 holdings

$255 Million is the total value of ARMISTICE CAPITAL, LLC's 34 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 81.8% .

 Value Shares↓ Weighting
BuySPDR S&P 500 ETF TRput$57,546,000
+41.1%
280,000
+40.0%
22.59%
+55.2%
ATRS BuyANTARES PHARMA INC$13,405,000
-16.3%
15,405,703
+16.4%
5.26%
-7.9%
VNDA SellVANDA PHARMACEUTICALS INC$13,376,000
-11.9%
1,600,000
-1.8%
5.25%
-3.0%
XNPT BuyXENOPORT INC$12,835,000
+116.5%
2,846,000
+163.5%
5.04%
+138.1%
RXDX BuyIGNYTA INC$11,428,000
-10.4%
1,688,000
+77.3%
4.49%
-1.4%
FRPT SellFRESHPET INC$10,057,000
-30.1%
1,372,000
-19.0%
3.95%
-23.1%
BCOR BuyBLUCORA INC$9,845,000
+20.5%
1,908,000
+128.8%
3.86%
+32.5%
ACOR BuyACORDA THERAPEUTICS INC$9,469,000
+0.6%
358,000
+62.7%
3.72%
+10.7%
HAIN  HAIN CELESTIAL GROUP INC$9,164,000
+1.3%
224,0000.0%3.60%
+11.4%
BDSI BuyBIODELIVERY SCIENCES$8,760,000
-30.2%
2,712,000
+3.5%
3.44%
-23.2%
HWAY BuyHEALTHWAYS INC$8,476,000
-8.5%
840,000
+16.7%
3.33%
+0.6%
TBPH NewTHERAVANCE BIOPHARMA INC$7,520,000400,000
+100.0%
2.95%
TLRDQ NewTAILORED BRANDS INC$7,160,000400,000
+100.0%
2.81%
LVS NewLAS VEGAS SANDS CORP$6,408,000124,000
+100.0%
2.52%
SGYPQ NewSYNERGY PHARMACEUTICALS DEL$6,072,0002,200,000
+100.0%
2.38%
ARRY NewARRAY BIOPHARMA INC$5,900,0002,000,000
+100.0%
2.32%
KATE SellKATE SPADE & CO$5,716,000
-5.4%
224,000
-34.1%
2.24%
+4.1%
AEGR BuyAEGERION PHARMACEUTICALS INC$5,543,000
-54.3%
1,498,000
+24.6%
2.18%
-49.8%
DMD SellDEMAND MEDIA INC$5,480,000
-13.8%
1,096,000
-5.2%
2.15%
-5.2%
NOMD NewNOMAD HLDGS LTD$5,118,000568,000
+100.0%
2.01%
BWLD NewBUFFALO WILD WINGS INC$4,740,00032,000
+100.0%
1.86%
TTWO NewTAKE-TWO INTERACTIVE SOFTWAR$4,671,000124,000
+100.0%
1.83%
PLAY NewDAVE & BUSTERS ENTMT INC$3,800,00098,000
+100.0%
1.49%
DECK SellDECKERS OUTDOOR CORP$3,595,000
-53.6%
60,000
-63.4%
1.41%
-48.9%
CHEF NewCHEFS WHSE INC$3,571,000176,000
+100.0%
1.40%
SPNC SellSPECTRANETICS CORP$2,497,000
-71.7%
172,000
-70.6%
0.98%
-68.9%
BuyPERNIX THERAPEUTICS HLDGS INdebt 4.250% 4/0$2,484,000
+383.3%
6,300,000
+215.0%
0.98%
+432.8%
TENX BuyTENAX THERAPEUTICS INC$2,399,000
-26.1%
1,170,000
+18.2%
0.94%
-18.7%
EXPR NewEXPRESS INC$2,312,000108,000
+100.0%
0.91%
RLOC BuyREACHLOCAL INC$1,656,000
+9.3%
925,000
+0.8%
0.65%
+20.1%
SEAS NewSEAWORLD ENTMT INC$1,179,00056,000
+100.0%
0.46%
MDGS BuyMEDIGUS LTDsponsored adr$1,128,000
-31.0%
619,816
+1.6%
0.44%
-24.0%
KODK NewEASTMAN KODAK CO$846,00078,000
+100.0%
0.33%
PTX NewPERNIX THERAPEUTICS HLDGS IN$611,000582,000
+100.0%
0.24%
BKS ExitBARNES & NOBLE INC$0-200,000
-100.0%
-0.62%
IILG ExitINTERVAL LEISURE GROUP INC$0-170,000
-100.0%
-0.95%
TUMI ExitTUMI HLDGS INC$0-188,000
-100.0%
-1.12%
ARCO ExitARCOS DORADOS HOLDINGS INC$0-1,180,000
-100.0%
-1.31%
GNCIQ ExitGNC HLDGS INC$0-122,000
-100.0%
-1.35%
ExitSEAWORLD ENTMT INC$0-234,000
-100.0%
-1.64%
VSTO ExitVISTA OUTDOOR INC$0-106,000
-100.0%
-1.68%
EXEL ExitEXELIXIS INC$0-1,270,000
-100.0%
-2.56%
THC ExitTENET HEALTHCARE CORP$0-252,000
-100.0%
-2.72%
FL ExitFOOT LOCKER INC$0-124,000
-100.0%
-2.88%
JCPNQ ExitJ.C. PENNEY CO INC$0-1,360,000
-100.0%
-3.23%
ENR ExitENERGIZER HLDGS INC NEW$0-300,000
-100.0%
-3.65%
THRX ExitTHERAVANCE BIOPHARMA INC$0-750,000
-100.0%
-4.39%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2016-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ENANTA PHARMACEUTICALS INC30Q3 20232.7%
SPDR S&P 500 ETF TR28Q3 202329.5%
MADRIGAL PHARMACEUTICALS INC27Q3 20232.9%
VANDA PHARMACEUTICALS INC26Q3 20219.4%
REGENERON PHARMACEUTICALS25Q3 20233.2%
ENERGIZER HLDGS INC NEW22Q2 20233.7%
ANTARES PHARMA INC21Q3 20206.6%
INCYTE CORP21Q3 20232.8%
VOYAGER THERAPEUTICS INC21Q3 20232.0%
BLUEBIRD BIO INC20Q4 20211.8%

View ARMISTICE CAPITAL, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ARMISTICE CAPITAL, LLC Q1 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Avalo Therapeutics, Inc.June 28, 2023588,8504.7%
Addex Therapeutics Ltd.February 16, 2023675,2955.0%
Arcadia Biosciences, Inc.February 14, 20232,675,40910.0%
Avinger IncFebruary 14, 2023789,40010.0%
Baudax Bio, Inc.February 14, 20231,165,7095.0%
BIORA THERAPEUTICS, INC.February 14, 202312,989,6485.7%
Bit Digital, IncFebruary 14, 20233,161,8893.7%
Bruush Oral Care Inc.February 14, 20231,122,92210.0%
CATALYST PHARMACEUTICALS, INC.Sold outFebruary 14, 202300.0%
Clarus Therapeutics Holdings, Inc.February 14, 20232,732,1695.0%

View ARMISTICE CAPITAL, LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View ARMISTICE CAPITAL, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export ARMISTICE CAPITAL, LLC's holdings